Phase III Randomized Study of Four Weeks High Dose IFN-α2b in Stage T2b No, T3a-bNo, T4a-b No, and T1-4, N1a, 2a (microscopic) Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet
known whether treatment with interferon alfa is more effective than observation alone for
stage II or stage III melanoma that has been completely removed surgically.
PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how
well it works compared to observation only in treating patients with stage II or stage III
melanoma that has been completely removed by surgery.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.